カテゴリ： GlobalData, アメリカ, 企業調査

Ligand Pharmaceuticals Inc (LGND)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012274
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：133
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company provides a diversified portfolio of biotechnology and pharmaceutical products. Its marketed product portfolio encompasses indication for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand’s clinical development portfolio comprises medications targeted at the treatment of seizure, cancer, diabetes, coma, cardiovascular disease, liver disease, muscle wasting, kidney disease, and others. In partnership with other pharmaceutical companies the company also offers late-stage development, regulatory management and commercialization support. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc (LGND) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 20
Venture Financing 22
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 22
Partnerships 23
Ligand Pharma Enters into Agreement with AiCuris 23
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 24
Symphogen Enters Into Agreement With Open Monoclonal Technology 25
Open Monoclonal Expands Agreement with CNA Development 26
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 27
Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 28
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 29
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 30
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 31
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 32
WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 33
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 34
Licensing Agreements 35
Amgen Enters into Licensing Agreement with Ligand Pharma 35
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 36
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 37
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 38
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 39
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 40
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 41
Novartis Enters into Licensing Agreement with Ligand Pharma 42
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 43
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 44
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 45
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 46
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 47
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 48
Sanofi Enters into Licensing Agreement with Ligand Pharma 49
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 50
Open Monoclonal Enters into Licensing Agreement with Celgene 51
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 52
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 53
Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 54
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 56
Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 57
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 58
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 59
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 60
TeneoBio Enters into Licensing Agreement with Ligand Pharma 61
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 62
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 63
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 64
RODES Enters into Licensing Agreement with Ligand Pharma 65
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 66
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 67
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 68
Open Monoclonal Enters into Licensing Agreement with Amgen 69
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 70
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 71
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 72
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 73
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 74
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 75
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 76
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 77
Ligand Pharma Enters Into Licencing Agreement With Merck 78
Ligand Pharma Enters Into Licensing Agreement With Hospira 79
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 80
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 81
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 82
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 83
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 84
Equity Offering 86
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 86
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 87
Debt Offering 88
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 88
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 90
Acquisition 91
Ligand Pharma to Acquire Crystal Bioscience 91
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 93
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 94
Ligand Pharma Acquires CyDex Pharma 95
Ligand Pharmaceuticals Inc – Key Competitors 97
Ligand Pharmaceuticals Inc – Key Employees 98
Ligand Pharmaceuticals Inc – Locations And Subsidiaries 99
Head Office 99
Other Locations & Subsidiaries 99
Recent Developments 101
Financial Announcements 101
Nov 09, 2017: Ligand Reports Third Quarter 2017 Financial Results 101
Aug 07, 2017: Ligand Reports Second Quarter 2017 Financial Results 104
May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 107
Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 110
Nov 03, 2016: Ligand Reports Third Quarter 2016 Financial Results 113
Aug 04, 2016: Ligand Reports Second Quarter 2016 Financial Results 116
May 04, 2016: Ligand Reports First Quarter 2016 Financial Results 119
Feb 10, 2016: Ligand Reports Fourth Quarter and Full Year 2015 Financial Results 122
Corporate Communications 125
Aug 21, 2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors 125
Clinical Trials 126
Feb 27, 2017: Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes 126
Sep 13, 2016: Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes 127
Aug 15, 2016: Results from Phase 1 Trials with Ligand LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism 128
Other Significant Developments 130
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies 130
Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 131
Appendix 133
Methodology 133
About GlobalData 133
Contact Us 133
Disclaimer 133

List of Tables
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 20
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 22
Ligand Pharma Enters into Agreement with AiCuris 23
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 24
Symphogen Enters Into Agreement With Open Monoclonal Technology 25
Open Monoclonal Expands Agreement with CNA Development 26
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 27
Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 28
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 29
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 30
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 31
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 32
WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 33
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 34
Amgen Enters into Licensing Agreement with Ligand Pharma 35
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 36
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 37
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 38
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 39
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 40
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 41
Novartis Enters into Licensing Agreement with Ligand Pharma 42
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 43
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 44
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 45
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 46
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 47
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 48
Sanofi Enters into Licensing Agreement with Ligand Pharma 49
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 50
Open Monoclonal Enters into Licensing Agreement with Celgene 51
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 52
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 53
Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 54
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 56
Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 57
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 58
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 59
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 60
TeneoBio Enters into Licensing Agreement with Ligand Pharma 61
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 62
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 63
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 64
RODES Enters into Licensing Agreement with Ligand Pharma 65
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 66
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 67
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 68
Open Monoclonal Enters into Licensing Agreement with Amgen 69
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 70
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 71
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 72
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 73
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 74
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 75
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 76
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 77
Ligand Pharma Enters Into Licencing Agreement With Merck 78
Ligand Pharma Enters Into Licensing Agreement With Hospira 79
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 80
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 81
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 82
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 83
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 84
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 86
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 87
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 88
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 90
Ligand Pharma to Acquire Crystal Bioscience 91
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 93
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 94
Ligand Pharma Acquires CyDex Pharma 95
Ligand Pharmaceuticals Inc, Key Competitors 97
Ligand Pharmaceuticals Inc, Key Employees 98
Ligand Pharmaceuticals Inc, Subsidiaries 99

★海外企業調査レポート[Ligand Pharmaceuticals Inc (LGND)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Sirtex Medical Ltd (SRX)：医療機器：M&Aディール及び事業提携情報
    Summary Sirtex Medical Ltd (Sirtex Medical) is a medical device company that develops and markets device for the treatment of liver cancer. The company’s sir-spheres microsphere is a medical device, which is used in selective internal radiation therapy for liver tumors. Its product Y-90 resin micros …
  • Operation Technology Inc：企業の戦略的SWOT分析
    Operation Technology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • QinetiQ Group plc：戦略・SWOT・企業財務分析
    QinetiQ Group plc - Strategy, SWOT and Corporate Finance Report Summary QinetiQ Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • LifeLabs Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary LifeLabsInc (LifeLabs), formerly MDS Diagnostic Services is a laboratory service provider that diagnoses, treats, monitors and prevent diseases in patients. The laboratory's services include clinical studies and services, drug and alcohol screening, employee wellness, hospital lab services, …
  • PGE Polska Grupa Energetyczna SA (PGE)：企業の財務・戦略的SWOT分析
    PGE Polska Grupa Energetyczna SA (PGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Orient Corporation：企業の戦略・SWOT・財務情報
    Orient Corporation - Strategy, SWOT and Corporate Finance Report Summary Orient Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Methanol Chemicals Co (2001)：企業の財務・戦略的SWOT分析
    Methanol Chemicals Co (2001) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Altaba Inc.：企業のM&A・事業提携・投資動向
    Altaba Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Altaba Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • National Fuel Gas Co (NFG)：企業の財務・戦略的SWOT分析
    National Fuel Gas Co (NFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Exelon Corporation (EXC)-エネルギー分野：企業M&A・提携分析
    Summary Exelon Corporation (Exelon) is a utility services holding company operating across the energy value chain comprising power generation, distribution, transmission and energy sales. It generates electricity from diverse sources, including nuclear, fossil fuels and renewable energy. Exelon deli …
  • TXU Energy Retail Company LLC：企業の戦略的SWOT分析
    TXU Energy Retail Company LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Enbridge Inc (ENB)：石油・ガス：M&Aディール及び事業提携情報
    Summary Enbridge Inc (Enbridge) is an integrated energy company. It carries out natural gas gathering, processing, transmission and distribution; transportation of crude oil; and marketing of petroleum products. The company also involved in power generation and transmission and has interests in rene …
  • Gujarat Sidhee Cement Ltd.：企業の戦略・SWOT・財務情報
    Gujarat Sidhee Cement Ltd. - Strategy, SWOT and Corporate Finance Report Summary Gujarat Sidhee Cement Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • University of California Los Angeles：医療機器：M&Aディール及び事業提携情報
    Summary University of California Los Angeles (UCLA) a subsidiary of University of California, is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, gradua …
  • Jardine Engineering Corporation, Limited：企業の戦略・SWOT・財務分析
    Jardine Engineering Corporation, Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Engineering Corporation, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Versum Materials, Inc. (VSM)：企業の財務・戦略的SWOT分析
    Versum Materials, Inc. (VSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Burger-In Oy：企業の戦略・SWOT・財務情報
    Burger-In Oy - Strategy, SWOT and Corporate Finance Report Summary Burger-In Oy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Rothschild & Co SCA：企業の戦略・SWOT・財務分析
    Rothschild & Co SCA - Strategy, SWOT and Corporate Finance Report Summary Rothschild & Co SCA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • TAP Biosystems Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary TAP Biosystems Ltd (TAP), a subsidiary of Sartorius Stedim Biotech GmbH is a provider of laboratory and pharmaceutical equipment. The company designs and manufactures automated cell culture, bio-reactor systems and fermentation systems. It also provides labware, consumables and accessories. …
  • Tosoh Corp (4042)：企業の財務・戦略的SWOT分析
    Tosoh Corp (4042) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆